These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 31620237)
1. Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity. R MM; Shandil R; Panda M; Sadler C; Ambady A; Panduga V; Kumar N; Mahadevaswamy J; Sreenivasaiah M; Narayan A; Guptha S; Sharma S; Sambandamurthy VK; Ramachandran V; Mallya M; Cooper C; Mdluli K; Butler S; Tommasi R; Iyer PS; Narayanan S; Chatterji M; Shirude PS ACS Med Chem Lett; 2019 Oct; 10(10):1480-1485. PubMed ID: 31620237 [TBL] [Abstract][Full Text] [Related]
2. Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis. Xiang W; He H; Duan X; He Z; Xu X; Liao M; Teng F; Li X; Luo T; Zeng J; Yu L; Gao C Microbiol Spectr; 2023 Sep; 11(5):e0472122. PubMed ID: 37698416 [TBL] [Abstract][Full Text] [Related]
3. Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities. Wang P; Batt SM; Wang B; Fu L; Qin R; Lu Y; Li G; Besra GS; Huang H J Med Chem; 2021 May; 64(9):6241-6261. PubMed ID: 33852302 [TBL] [Abstract][Full Text] [Related]
4. Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors. Balabon O; Pitta E; Rogacki MK; Meiler E; Casanueva R; Guijarro L; Huss S; Lopez-Roman EM; Santos-Villarejo Á; Augustyns K; Ballell L; Aguirre DB; Bates RH; Cunningham F; Cacho M; Van der Veken P J Med Chem; 2020 May; 63(10):5367-5386. PubMed ID: 32342688 [TBL] [Abstract][Full Text] [Related]
5. Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis. Kb S; Kumari A; Shetty D; Fernandes E; Dv C; Jays J; Murahari M J Mol Graph Model; 2020 Dec; 101():107718. PubMed ID: 32949960 [TBL] [Abstract][Full Text] [Related]
7. Identification of a Chemical Inhibitor with a Novel Scaffold Targeting Decaprenylphosphoryl-β-D-Ribose Oxidase (DprE1). Matsunaga T; Monobe K; Aoki S Infect Disord Drug Targets; 2023; 23(5):e090323214508. PubMed ID: 36892121 [TBL] [Abstract][Full Text] [Related]
9. Chemical Space Exploration of DprE1 Inhibitors Using Chemoinformatics and Artificial Intelligence. Chhabra S; Kumar S; Parkesh R ACS Omega; 2021 Jun; 6(22):14430-14441. PubMed ID: 34124465 [TBL] [Abstract][Full Text] [Related]
10. Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. Panda M; Ramachandran S; Ramachandran V; Shirude PS; Humnabadkar V; Nagalapur K; Sharma S; Kaur P; Guptha S; Narayan A; Mahadevaswamy J; Ambady A; Hegde N; Rudrapatna SS; Hosagrahara VP; Sambandamurthy VK; Raichurkar A J Med Chem; 2014 Jun; 57(11):4761-71. PubMed ID: 24818517 [TBL] [Abstract][Full Text] [Related]
11. Decaprenylphosphoryl-β-D-ribose 2'-epimerase, the target of benzothiazinones and dinitrobenzamides, is an essential enzyme in Mycobacterium smegmatis. Crellin PK; Brammananth R; Coppel RL PLoS One; 2011 Feb; 6(2):e16869. PubMed ID: 21346818 [TBL] [Abstract][Full Text] [Related]
12. Lead optimization of 1,4-azaindoles as antimycobacterial agents. Shirude PS; Shandil RK; Manjunatha MR; Sadler C; Panda M; Panduga V; Reddy J; Saralaya R; Nanduri R; Ambady A; Ravishankar S; Sambandamurthy VK; Humnabadkar V; Jena LK; Suresh RS; Srivastava A; Prabhakar KR; Whiteaker J; McLaughlin RE; Sharma S; Cooper CB; Mdluli K; Butler S; Iyer PS; Narayanan S; Chatterji M J Med Chem; 2014 Jul; 57(13):5728-37. PubMed ID: 24874895 [TBL] [Abstract][Full Text] [Related]
13. Discovery of Yang L; Hu X; Lu Y; Xu R; Xu Y; Ma W; Alam MS; Zhang T; Chai X; Lei Y; Ye Q; Dong X; Kang Y; Che J; Hou T; Li D J Med Chem; 2024 Feb; 67(3):1914-1931. PubMed ID: 38232131 [TBL] [Abstract][Full Text] [Related]
14. The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis. Makarov V; Neres J; Hartkoorn RC; Ryabova OB; Kazakova E; Šarkan M; Huszár S; Piton J; Kolly GS; Vocat A; Conroy TM; Mikušová K; Cole ST Antimicrob Agents Chemother; 2015 Aug; 59(8):4446-52. PubMed ID: 25987616 [TBL] [Abstract][Full Text] [Related]
16. Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis. Trefzer C; Rengifo-Gonzalez M; Hinner MJ; Schneider P; Makarov V; Cole ST; Johnsson K J Am Chem Soc; 2010 Oct; 132(39):13663-5. PubMed ID: 20828197 [TBL] [Abstract][Full Text] [Related]
17. Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones. Li P; Wang B; Zhang X; Batt SM; Besra GS; Zhang T; Ma C; Zhang D; Lin Z; Li G; Huang H; Lu Y Eur J Med Chem; 2018 Dec; 160():157-170. PubMed ID: 30336450 [TBL] [Abstract][Full Text] [Related]
19. Structure-based drug design and characterization of novel pyrazine hydrazinylidene derivatives with a benzenesulfonate scaffold as noncovalent inhibitors of DprE1 tor tuberculosis treatment. Shivakumar ; Dinesha P; Udayakumar D Mol Divers; 2024 Mar; ():. PubMed ID: 38448719 [TBL] [Abstract][Full Text] [Related]